骨康胶囊致不良反应93例分析  

Analysis of 93 Cases of ADR Report Caused by Gukang Capsules

作　　者：单小雯 梁锦锋 单伟光[1] 王泳俨[3] 

机构地区：[1]浙江工业大学药学院,杭州310014 [2]浙江省药品不良反应监测中心,杭州310012 [3]解放军后勤工程学院,重庆404100

出　　处：《中国药房》2015年第2期236-239,共4页China Pharmacy

摘　　要：目的：了解骨康胶囊致不良反应（ADR）的基本情况,探讨其发生规律,为临床合理用药提供参考。方法：对浙江省ADR监测中心2006年1月1日-2014年5月21日收集到的骨康胶囊致ADR报告进行统计和分析。结果：骨康胶囊致ADR共159例,涉及全身多个器官/系统,其中以胃肠系统损害居多（39例,35.85%）;30~59岁年龄段ADR病例较多（58例,62.37%）;性别间无显著性差异;原患疾病多为骨折。在27例严重ADR病例中,肝胆系统损害居多（25例,56.82%）。结论：临床应警惕骨康胶囊所致的肝毒性,根据患者病情严格控制剂量,保证用药安全。OBJECTIVE： To understand the general information of Gukang capsules-induced ADR, investigate the general reg- ularity and provide reference for rational drug use in the clinic. METHODS： Gukang capsules-induced ADR reports obtained from Zhejiang ADR Monitoring Center from Jan. 1, 2006 to May 21, 2014 were analyzed statistically. RESULTS： There were 159 cas- es of Gukang capsules-induced ADR in total, involving multiple organs and systems; the damage to the gastrointestinal system took the largest proportion （39 cases, 35.85% ）. Cases of ADR patients in 30-59 years old stand high （58 cases, 62.37% ）; there were no significant gender differences; primary disease were mostly fractures. Among 27 cases of severe ADR cases, damage to the hepatobiliary system was in the majority （25 cases, 56.82% ）. CONCLUSIONS： Great importance should be attached to hepa- totoxicity caused by Gukang capsules. Drug dosage should be strictly controlled according to the patients diseases to ensure the safety of drug use.

关 键 词：骨康胶囊 药品不良反应 回顾性分析 

分 类 号：R287[医药卫生—中药学] R969.3[医药卫生—中医学]